Kashi Clinical Laboratories, a leader in high-complexity laboratory testing, is excited to announce the successful implementation of Next Generation Sequencing (NGS) for the identification of SARS-CoV-2, the virus that causes COVID-19. SARS-CoV-2 variants have been detected globally, many spreading more rapidly than others. In the battle to contain COVID-19 identifying these variants in a population is crucial. NGS can identify and characterize these variants as they arise.
As a current provider of diagnostic testing using RT-PCR technology, Kashi is able to use this new method to sequence viral genome of positive samples to determine the presence of novel variants in these samples. This will provide our partners and public health officials with the critical information as we all face the growing concern with this rapidly spreading virus.
At Kashi we understand the trust you have in us today is more crucial than ever before.
For more information go here.